The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease

Current Diabetes Reports

Volumn 6, Issue 1, 2006, Pages 8-16

  Kalantarinia, Kambiz ^a   Okusa, Mark D ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORTALITY; PATHOPHYSIOLOGY; POTASSIUM RESTRICTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNITED STATES;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33645289976     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0045-4     Document Type: Review

References (65)

1. Gilbertson DT, Liu J, Xue JL, et al.: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736-3741.
2. Jones CA, McQuillan GM, Kusek JW, et al.: Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998, 32:992-999.
3. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
4. Gall MA, Borch-Johnsen K, Hougaard P. et al.: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303-1309.
5. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992, 41:731-735.
6. Tuttle KR, Puhlman ME, Cooney SK, Short R: Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis 1999, 34:918-925.
7. 3 annual report: ESRD clinical performance measures project [no authors listed]. Am J Kidney Dis 2004, 44:A5-A6, S1-S92.
8. Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
9. Tokmakova MP, Skali H, Kenchaiah S. et al.: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004, 110:3667-3673.
10. Ravid M, Brosh D, Ravid-Safran D, et al.: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998, 158:998-1004.
11. Naftilan AJ: Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens 1994, 3:218-227.
12. Dzau VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993, 153:937-942.
13. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000, 77:S93-S98.
14. Weiss D, Sorescu D, Taylor WR: Angiotensin II and atherosclerosis. Am J Cardiol 2001, 87:25C-32C.
15. Gainer JV, Morrow JD, Loveland A, et al.: Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998, 339: 1285-1292.
16. Wei CC, Tian B, Perry G, et al.: Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol 2002, 282:H2254-H2258.
17. van den Meiracker AH, Man in't Veld AJ, Admiraal PJ, et al.: Partial escape of angiotensin converting enzyme (ACE) Inhibition during prolonged ACE Inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992, 10:803-812.
18. Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardlal infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33:40-45.
19. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16(suppl N):103-106.
20. Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma anglotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53-57.
21. Siragy HM, Carey RM: Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001, 10:99-103.
22. Okada H, Watanabe Y, Kikuta T, et al.: Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 2004, 15:2404-2413.
23. Schanstra JP, Neau E, Drogoz P, et al.: In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002, 110:371-379.
24. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
25. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925-1930.
26. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate dedine in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 128:982-988.
27. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
28. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997, 20:1576-1581.
29. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
30. Mathiesen ER, Hommel E, Hansen HP, et al.: Randomised controlled trial of long-term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999, 319:24-25.
31. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497-504.
32. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275-279.
33. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-678.
34. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
35. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
36. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
37. Trevisan R, Tiengo A: Effect of low-dose ramlpril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995, 8:876-883.
38. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group [no authors listed]. Lancet 1997, 349:1787-1792.
39. Kshirsagar AV, Joy MS, Hogan SL, et al.: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000, 35:695-707.
40. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
41. Rossing K, Christensen PK, Andersen S, et al.: Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care 2003, 26:569-574.
42. Barnett AH, Bain SC, Bouter P. et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
43. Strippoli GF. Craig M, Deeks JJ, et al.: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004, 329:828.
44. Cohn JN, Tognoni C: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
45. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
46. Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
47. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
48. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
49. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
50. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
51. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
52. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
53. Papademetriou V, Farsang C, Elmfeldt D, et al.: Stroke prevention with the angiotensin II type-1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004, 44:1175-1180.
54. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970-975.
55. Lee VC, Rhew DC, Dylan M, et al.: Meta-analysis: anglotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004, 141:693-704.
56. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
57. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353: 611-616.
58. Rosner MH, Okusa MD: Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med 2003, 163:1025-1029.
59. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560-2572.
60. Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874-1880.
61. Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1019-1024.
62. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and anglotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992-999.
63. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95-100.
64. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268-2274.
65. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.